UBS AM’s Revance Therapeutics, Inc. RVNC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q1
Sell
-237,409
Closed -$722K 2723
2024
Q4
$722K Sell
237,409
-27,801
-10% -$84.5K ﹤0.01% 2466
2024
Q3
$1.38M Buy
265,210
+27,420
+12% +$142K ﹤0.01% 2224
2024
Q2
$611K Buy
237,790
+118,429
+99% +$304K ﹤0.01% 2575
2024
Q1
$587K Hold
119,361
﹤0.01% 2236
2023
Q4
$1.05M Buy
119,361
+8,686
+8% +$76.4K ﹤0.01% 1997
2023
Q3
$1.27M Buy
110,675
+19,761
+22% +$227K ﹤0.01% 1829
2023
Q2
$2.93M Hold
90,914
﹤0.01% 1468
2023
Q1
$2.93M Buy
90,914
+11,928
+15% +$384K ﹤0.01% 1468
2022
Q4
$1.46M Buy
78,986
+9,171
+13% +$169K ﹤0.01% 1681
2022
Q3
$1.89M Buy
69,815
+983
+1% +$26.5K ﹤0.01% 1630
2022
Q2
$951K Buy
68,832
+3,001
+5% +$41.5K ﹤0.01% 1995
2022
Q1
$1.28M Hold
65,831
﹤0.01% 2013
2021
Q4
$1.07M Sell
65,831
-296,717
-82% -$4.84M ﹤0.01% 2176
2021
Q3
$10.1M Sell
362,548
-7,746
-2% -$216K ﹤0.01% 1094
2021
Q2
$11M Sell
370,294
-13,862
-4% -$411K ﹤0.01% 1092
2021
Q1
$10.7M Buy
384,156
+9,480
+3% +$265K ﹤0.01% 1064
2020
Q4
$10.6M Buy
374,676
+332,453
+787% +$9.42M 0.01% 1035
2020
Q3
$1.06M Buy
42,223
+1,288
+3% +$32.4K ﹤0.01% 1826
2020
Q2
$1,000K Buy
40,935
+5,871
+17% +$143K ﹤0.01% 1810
2020
Q1
$519K Buy
35,064
+4,899
+16% +$72.5K ﹤0.01% 1966
2019
Q4
$490K Buy
30,165
+16,078
+114% +$261K ﹤0.01% 2246
2019
Q3
$183K Buy
14,087
+1,055
+8% +$13.7K ﹤0.01% 2598
2019
Q2
$169K Hold
13,032
﹤0.01% 2576
2019
Q1
$205K Buy
+13,032
New +$205K ﹤0.01% 2447
2016
Q1
Sell
-9,300
Closed -$318K 2674
2015
Q4
$318K Buy
9,300
+600
+7% +$20.5K ﹤0.01% 2310
2015
Q3
$259K Hold
8,700
﹤0.01% 2369
2015
Q2
$278K Buy
+8,700
New +$278K ﹤0.01% 2412
2015
Q1
Sell
-65,200
Closed -$1.1M 2653
2014
Q4
$1.1M Hold
65,200
﹤0.01% 1550
2014
Q3
$1.26M Hold
65,200
﹤0.01% 1478
2014
Q2
$2.22M Buy
65,200
+16,900
+35% +$575K ﹤0.01% 1295
2014
Q1
$1.52M Buy
+48,300
New +$1.52M ﹤0.01% 1416